News ReleaseView printer-friendly version
Quidel Reports Third Quarter 2017 Financial Results
Third Quarter 2017 Financial Highlights
Total revenue was
$50.9 millionas compared to $49.3 millionin the third quarter of 2016.
- Total Immunoassay product revenue increased 19% from the third quarter of 2016.
- Total Molecular revenues increased 13% from the third quarter of 2016.
Reported GAAP EPS of $(0.16) per share in the third quarter of 2017,
as compared to $(0.02) per share in the third quarter of 2016 and
reported non-GAAP EPS of $0.17 per diluted share in the third quarter
of 2017, as compared to
$0.10per diluted share in the third quarter of 2016.
Recent Operational Highlights
Announced definitive agreements to acquire Alere Triage® and B-type
Naturietic Peptide (BNP) Assay business run on
Beckman CoulterAnalyzers, which subsequently closed on October 6, 2017.
- Received FDA Clearance for Its Solana® RSV + hMPV Assay.
Received FDA Clearance for
Its Point-of-Care Sofia® Lyme FIA.
Third Quarter 2017 Results
Total revenue for the third quarter of 2017 increased 3% over the third
quarter of 2016 to
Immunoassay product revenue increased 19% in the third quarter, as
“Quidel has transformed itself with the completion of the acquisition of
the Alere Triage and B-type Naturietic Peptide (BNP) Assay businesses,
which we closed in early October. This transaction broadens our business
by unlocking growth opportunities in several new end markets, both
geographically and by product. We are well underway in our efforts to
bring together these two strong organizations and look forward to
providing updates as we move through the process,” said
Cost of Sales in the third quarter of 2017 increased
Net loss for the third quarter of 2017 was
Results for the Nine Months Ended
Total revenues increased 17% to $162.9 million for the nine-month period ended September 30, 2017, as compared to $138.8 million for the same period in 2016. The increase in revenues was primarily driven by greater sales of Immunoassay and Molecular products that were partially offset by decreases in Virology and Grant revenue.
Immunoassay product revenue increased 37% in the nine-month period ended
September 30, 2017, as
For the nine-month period ended September 30, 2017, total costs and
expenses were $157.2 million as compared to $149.1 million over the same
period in 2016. Cost of Sales increased by
For the first nine-months of 2017, net loss was $3.1 million, or $(0.09) per share, as compared to a net loss of $11.9 million, or $(0.36) per share, for the same nine-month period in 2016. On a non-GAAP basis, excluding amortization of intangibles, stock compensation expense and certain non-recurring items, net income for the nine months ended September 30, 2017 was $17.2 million, or $0.50 per diluted share, as compared to net income of $0.4 million, or $0.01 per diluted share, for the first nine months of 2016.
Non-GAAP Financial Information
The Company is providing non-GAAP financial information to exclude the effect of stock-based compensation, amortization of intangibles and certain non-recurring items on income (loss) and net earnings (loss) per share as a supplement to its consolidated financial statements, which are presented in accordance with generally accepted accounting principles in the U.S., or GAAP.
Management is providing the adjusted net income (loss) and adjusted net earnings (loss) per share information for the periods presented because it believes this enhances the comparison of the Company’s financial performance from period-to-period, and to that of its competitors. This press release is not meant to be considered in isolation, or as a substitute for results prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measures to the comparable GAAP measures is included in this press release as part of the attached financial tables.
Conference Call Information
To participate in the live call by telephone from the U.S., dial 877-930-5791, or from outside the U.S. dial 253-336-7286, and enter the pass code 1067380.
A live webcast of the call can be accessed on the Investor Relations
section of the
Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and InflammaDry® leading brand names, as well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's recently acquired Triage® system of tests comprises a comprehensive test menu that provides rapid, cost-effective treatment decisions at the point-of-care (POC), offering a diverse immunoassay menu in a variety of tests to provide you with diagnostic answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians’ offices and hospital and reference laboratories. For more information about Quidel’s comprehensive product portfolio, visit quidel.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, fluctuations in our operating results resulting from seasonality, the timing of the onset, length and severity of cold and flu seasons, government and media attention focused on influenza and the related potential impact on humans from novel influenza viruses, adverse changes in competitive conditions in domestic and international markets, changes in sales levels as it relates to the absorption of our fixed costs, lower than anticipated market penetration of our products, the reimbursement system currently in place and future changes to that system, changes in economic conditions in our domestic and international markets, the quantity of our product in our distributors’ inventory or distribution channels, changes in the buying patterns of our distributors, and changes in the healthcare market and consolidation of our customer base; our development and protection of intellectual property; our development of new technologies, products and markets; our reliance on a limited number of key distributors; our reliance on sales of our influenza diagnostics tests; our ability to manage our growth strategy; our ability to integrate companies or technologies we have acquired or may acquire, including integration and transition risks, the ability to achieve anticipated financial results and synergies, and effects of disruptions or threatened disruptions to our relationships, or those of the acquired businesses, with distributors, suppliers, customers and employees; intellectual property risks, including but not limited to, infringement litigation; our debt service requirements; our inability to settle conversions of our Convertible Senior Notes in cash; the effect on our operating results from the trigger of the conditional conversion feature of our Convertible Senior Notes; the possibility that we may incur additional indebtedness; our need for additional funds to finance our operating needs; volatility and disruption in the global capital and credit markets; acceptance of our products among physicians and other healthcare providers; competition with other providers of diagnostic products; adverse actions or delays in new product reviews or related to currently-marketed products by the FDA or any loss of previously received regulatory approvals or clearances; changes in government policies; compliance with other government regulations, such as safe working conditions, manufacturing practices, environmental protection, fire hazard and disposal of hazardous substances; third-party reimbursement policies; our ability to meet demand for our products; interruptions in our supply of raw materials; product defects; business risks not covered by insurance and exposure to other litigation claims; interruption to our computer systems; competition for and loss of management and key personnel; international risks, including but not limited to, compliance with product registration requirements, exposure to currency exchange fluctuations and foreign currency exchange risk sharing arrangements, longer payment cycles, lower selling prices and greater difficulty in collecting accounts receivable, reduced protection of intellectual property rights, political and economic instability, taxes, and diversion of lower priced international products into U.S. markets; dilution resulting from future sales of our equity; volatility in our stock price; provisions in our charter documents, Delaware law and our Convertible Senior Notes that might delay or impede stockholder actions with respect to business combinations or similar transactions; and our intention of not paying dividends. Forward-looking statements typically are identified by the use of terms such as “may,” “will,” “should,” “might,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” and similar words, although some forward-looking statements are expressed differently. The risks described in reports and registration statements that we file with the Securities and Exchange Commission (the “SEC”) from time to time, should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this press release. Except as required by law, we undertake no obligation to publicly release the results of any revision or update of these forward-looking statements, whether as a result of new information, future events or otherwise.
|CONSOLIDATED STATEMENTS OF OPERATIONS|
(In thousands, except per share data; unaudited)
|Three Months Ended September 30,|
|Cost of sales (excludes amortization of intangible assets from acquired businesses and technology)||19,391||17,728|
|Research and development||7,468||8,801|
|Sales and marketing||12,898||11,853|
|General and administrative||6,580||6,364|
|Amortization of intangible assets from acquired businesses and technology||2,503||2,273|
|Acquisition and integration costs||4,591||197|
|Total costs and expenses||53,431||47,216|
|Operating (loss) income||(2,537||)||2,125|
|Interest expense, net||(2,784||)||(3,006||)|
|Loss before income taxes||(5,321||)||(881||)|
|Provision (benefit) for income taxes||204||(309||)|
|Basic and diluted loss per share||$||(0.16||)||$||(0.02||)|
|Shares used in basic and diluted per share calculation||33,913||32,673|
|Gross profit as a % of total revenues||62||%||64||%|
|Research and development as a % of total revenues||15||%||18||%|
|Sales and marketing as a % of total revenues||25||%||24||%|
|General and administrative as a % of total revenues||13||%||13||%|
|Condensed balance sheet data (in thousands):||9/30/2017||12/31/2016|
|Cash and cash equivalents||$||172,994||$||169,508|
|Accounts receivable, net||41,575||24,990|
|Nine Months Ended September 30,|
|Cost of sales (excludes amortization of intangible assets from acquired businesses and technology)||60,716||54,295|
|Research and development||22,970||31,164|
|Sales and marketing||38,813||36,376|
|General and administrative||20,483||19,964|
|Amortization of intangible assets from acquired businesses and technology||7,184||6,782|
|Acquisition and integration costs||7,022||568|
|Total costs and expenses||157,188||149,149|
|Operating income (loss)||5,665||(10,354||)|
|Interest expense, net||(8,387||)||(8,619||)|
|Loss before income taxes||(2,722||)||(18,973||)|
|Provision (benefit) for income taxes||355||(7,115||)|
|Basic and diluted loss per share||$||(0.09||)||$||(0.36||)|
|Shares used in basic and diluted per share calculation||33,538||32,645|
|Gross profit as a % of total revenues||63||%||61||%|
|Research and development as a % of total revenues||14||%||22||%|
|Sales and marketing as a % of total revenues||24||%||26||%|
|General and administrative as a % of total revenues||13||%||14||%|
|Three Months Ended September 30,||Nine Months Ended September 30,|
Consolidated net revenues by product
|Royalties, grants and other||268||4,224||1,475||8,616|
|Reconciliation of Non-GAAP Financial Information|
|(In thousands, except per share data; unaudited)|
|Three months ended September 30,||Nine months ended September 30,|
|Net loss - GAAP||$||(5,525||)||$||(572||)||$||(3,077||)||$||(11,858||)|
|Non-cash stock compensation expense||1,879||1,734||5,938||5,820|
|Amortization of intangibles||2,720||2,381||7,605||7,132|
|Amortization of debt discount and issuance costs||1,388||1,343||4,129||4,022|
|Acquisition and integration costs||4,591||197||7,022||568|
|Income tax impact of valuation allowance for deferred tax assets||4,590||137||4,264||852|
Income tax impact of non-cash stock compensation expense, amortization of intangibles, debt discount and issuance costs and acquisition and integration costs
|Adjusted net income||$||5,943||$||3,240||$||17,241||$||396|
|Basic earnings (loss) per share:|
|Adjusted net earnings||$||0.18||$||0.10||$||0.51||$||0.01|
|Net loss - GAAP||$||(0.16||)||$||(0.02||)||$||(0.09||)||$||(0.36||)|
|Diluted earnings (loss) per share:|
|Adjusted net earnings||$||0.17||$||0.10||$||0.50||$||0.01|
|Net loss - GAAP||$||(0.16||)||$||(0.02||)||$||(0.09||)||$||(0.36||)|
Chief Financial Officer
Media and Investors Contact: